Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in Turkey: Inferences from GARFIELD-AF registry

Basit Öğe Kaydı
dc.contributor.authorSayin, Begum Yetis
dc.contributor.authorOkutucu, Sercan
dc.contributor.authorYilmaz, Mehmet Birhan
dc.contributor.authorOzdemir, Kurtulus
dc.contributor.authorAydinlar, Ali
dc.contributor.authorSahin, Durmus Yildiray
dc.contributor.authorAltun, Armagan
dc.date.accessioned2024-02-23T14:29:36Z
dc.date.available2024-02-23T14:29:36Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractObjective: The corner stone of atrial fibrillation therapy includes the prevention of stroke with less adverse effects. The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) study provided data to compare treatment strategies in Turkey with other populations and every-day practice of stroke prevention management with complications. Methods: GARFIELD-AF is a large-scale registry that enrolled 52,014 patients in five sequential cohorts at > 1.000 centers in 35 countries. This study was initiated to track the evolution of global anticoagulation practice, and to study the impact of NOAC therapy in AF. A total of 756 patients from 17 enrolling sites in Turkey were in cohort 4 and 5. Treatment strategies at diagnosis initiated by CHA(2)DS(2)-VASc score, baseline characteristics of patients, treatment according to stroke and bleeding risk profiles, and INR values were analyzed in cohorts. Additionally, event rates during the first year follow up were evaluated. Results: AF patients in Turkey were mostly seen in young women. Stroke risk according to the CHADS(2) score and CHA(2)DS(2)-VASc score compared with world data. The mean of risk score values, including HAS-BLED score were lower in Turkey than in the world data. The percentage of patients receiving FXa inhibitor with or without an antiplatelet usage was more than the other drug groups. All-cause mortality was higher in Turkey. Different form world data when HAS-BLED score was above 3, the therapy was mostly changed to antiplatelet drugs in Turkey. Conclusion: In addition to deficiencies in available treatment options, patient care and clinical outcomes of patients with AF, the data of GARFIELD-AF provide data from Turkey about therapeutic strategies and best practices.en_US
dc.identifier.doi10.14744/AnatolJCardiol.2019.78178
dc.identifier.endpage280en_US
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue5en_US
dc.identifier.pmid31062761en_US
dc.identifier.scopus2-s2.0-85065650573en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage272en_US
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2019.78178
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14761
dc.identifier.volume21en_US
dc.identifier.wosWOS:000468584800007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Soc Cardiologyen_US
dc.relation.ispartofAnatolian Journal Of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAtrial Fibrillationen_US
dc.subjectAnticoagulationen_US
dc.subjectStrokeen_US
dc.titleAntithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in Turkey: Inferences from GARFIELD-AF registryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu